Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 12, 2017
- Accepted in final form September 29, 2017
- First Published January 3, 2018.
Article Versions
- Previous version (January 3, 2018 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Motoki Fujimaki, MD,
- Shinji Saiki, MD, PhD,
- Yuanzhe Li, PhD,
- Naoko Kaga, PhD,
- Hikari Taka, PhD,
- Taku Hatano, MD, PhD,
- Kei-Ichi Ishikawa, MD, PhD,
- Yutaka Oji, MD,
- Akio Mori, MD,
- Ayami Okuzumi, MD,
- Takahiro Koinuma, MD,
- Shin-Ichi Ueno, MD,
- Yoko Imamichi, BS,
- Takashi Ueno, PhD,
- Yoshiki Miura, PhD,
- Manabu Funayama, PhD and
- Nobutaka Hattori, MD, PhD
- Motoki Fujimaki, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shinji Saiki, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Grant from Ministry of Education, Culture, Sports, Science and Technology (25111007) (2) Grant from Ministry of Education, Culture, Sports, Science and Technology (25111001) (3) Grant from Japan Society for the Promotion of Science (15H04843)
NONE
NONE
NONE
NONE
NONE
NONE
- Yuanzhe Li, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Naoko Kaga, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) JSPS KAKENHI,#JP16K01834,site investigator, 2016-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hikari Taka, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)JSPS KAKENHI,#JP16K01834, Lead investigator,2016-2018 (2)JSPS KAKENHI,#JP17K08670, Site investigator,2017-2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Taku Hatano, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
The Japanese Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid for Scientific Research 16K09675, Principal investigator, 2016-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kei-Ichi Ishikawa, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yutaka Oji, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Akio Mori, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ayami Okuzumi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Takahiro Koinuma, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shin-Ichi Ueno, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yoko Imamichi, BS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Takashi Ueno, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yoshiki Miura, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Manabu Funayama, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Juntendo University School of Medicine, 25-23, Project Research Grants- in-Aid, 2013.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nobutaka Hattori, MD, PhD
NONE
NONE
NONE
Movement Disorders-Clinical Practice, Journal of Neural Transmission, Neuroscience Research, JNNP, J of Parkinson's disease
NONE
NONE
NONE
Hisamitsu Pharmaceutical, Dai-Nippon Sumitomo Pharma Co.,Ltd., Kyowa Hakko Kirin,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan.
- Correspondence
Dr. Saiki ssaiki{at}juntendo.ac.jp or Dr. Hattori nhattori{at}juntendo.ac.jp
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jeffrey Allen and Dr. Nicholas Purcell
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriersA metabolomic studyGrace F. Crotty, Romeo Maciuca, Eric A. Macklin et al.Neurology, September 30, 2020 -
Article
The scientific and clinical basis for the treatment of Parkinson disease (2009)C. Warren Olanow, Matthew B. Stern, Kapil Sethi et al.Neurology, May 26, 2009 -
Articles
Caffeine, postmenopausal estrogen, and risk of Parkinson’s diseaseA. Ascherio, H. Chen, M.A. Schwarzschild et al.Neurology, March 11, 2003 -
Articles
Caffeinated clues from epidemiology of Parkinson’s diseaseAlberto Ascherio, Honglei Chen et al.Neurology, December 08, 2003